Literature DB >> 29569852

Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis.

Sebastiaan J Vastert1, Peter A Nigrovic2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29569852      PMCID： PMC6105394          DOI： 10.1002/art.40501

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  12 in total

1.  Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

Authors:  Sebastiaan J Vastert; Wilco de Jager; Bo Jan Noordman; Dirk Holzinger; Wietse Kuis; Berent J Prakken; Nico M Wulffraat
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

Review 2.  Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?

Authors:  Peter A Nigrovic
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

Review 3.  Advances in biomarkers for paediatric rheumatic diseases.

Authors:  Alessandro Consolaro; Giulia C Varnier; Alberto Martini; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2014-12-16       Impact factor: 20.543

4.  Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).

Authors:  Peter A Nigrovic; Timothy Beukelman; George Tomlinson; Brian M Feldman; Laura E Schanberg; Yukiko Kimura
Journal:  Clin Trials       Date:  2018-03-15       Impact factor: 2.486

5.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

Authors:  Fabrizio De Benedetti; Hermine I Brunner; Nicolino Ruperto; Andrew Kenwright; Stephen Wright; Inmaculada Calvo; Ruben Cuttica; Angelo Ravelli; Rayfel Schneider; Patricia Woo; Carine Wouters; Ricardo Xavier; Lawrence Zemel; Eileen Baildam; Ruben Burgos-Vargas; Pavla Dolezalova; Stella M Garay; Rosa Merino; Rik Joos; Alexei Grom; Nico Wulffraat; Zbigniew Zuber; Francesco Zulian; Daniel Lovell; Alberto Martini
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

6.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.

Authors:  Virginia Pascual; Florence Allantaz; Edsel Arce; Marilynn Punaro; Jacques Banchereau
Journal:  J Exp Med       Date:  2005-04-25       Impact factor: 14.307

7.  IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Authors:  Victoria L Arthur; Emily Shuldiner; Elaine F Remmers; Anne Hinks; Alexei A Grom; Dirk Foell; Alberto Martini; Marco Gattorno; Seza Özen; Sampath Prahalad; Andrew S Zeft; John F Bohnsack; Norman T Ilowite; Elizabeth D Mellins; Ricardo Russo; Claudio Len; Sheila Oliveira; Rae S M Yeung; Alan M Rosenberg; Lucy R Wedderburn; Jordi Anton; Johannes-Peter Haas; Angela Rösen-Wolff; Kirsten Minden; Ann Marie Szymanski; Wendy Thomson; Daniel L Kastner; Patricia Woo; Michael J Ombrello
Journal:  Arthritis Rheumatol       Date:  2018-06-28       Impact factor: 10.995

8.  HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.

Authors:  Michael J Ombrello; Elaine F Remmers; Ioanna Tachmazidou; Alexei Grom; Dirk Foell; Johannes-Peter Haas; Alberto Martini; Marco Gattorno; Seza Özen; Sampath Prahalad; Andrew S Zeft; John F Bohnsack; Elizabeth D Mellins; Norman T Ilowite; Ricardo Russo; Claudio Len; Maria Odete E Hilario; Sheila Oliveira; Rae S M Yeung; Alan Rosenberg; Lucy R Wedderburn; Jordi Anton; Tobias Schwarz; Anne Hinks; Yelda Bilginer; Jane Park; Joanna Cobb; Colleen L Satorius; Buhm Han; Elizabeth Baskin; Sara Signa; Richard H Duerr; J P Achkar; M Ilyas Kamboh; Kenneth M Kaufman; Leah C Kottyan; Dalila Pinto; Stephen W Scherer; Marta E Alarcón-Riquelme; Elisa Docampo; Xavier Estivill; Ahmet Gül; Paul I W de Bakker; Soumya Raychaudhuri; Carl D Langefeld; Susan Thompson; Eleftheria Zeggini; Wendy Thomson; Daniel L Kastner; Patricia Woo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

9.  Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.

Authors:  Michael J Ombrello; Victoria L Arthur; Elaine F Remmers; Anne Hinks; Ioanna Tachmazidou; Alexei A Grom; Dirk Foell; Alberto Martini; Marco Gattorno; Seza Özen; Sampath Prahalad; Andrew S Zeft; John F Bohnsack; Norman T Ilowite; Elizabeth D Mellins; Ricardo Russo; Claudio Len; Maria Odete E Hilario; Sheila Oliveira; Rae S M Yeung; Alan M Rosenberg; Lucy R Wedderburn; Jordi Anton; Johannes-Peter Haas; Angela Rosen-Wolff; Kirsten Minden; Klaus Tenbrock; Erkan Demirkaya; Joanna Cobb; Elizabeth Baskin; Sara Signa; Emily Shuldiner; Richard H Duerr; Jean-Paul Achkar; M Ilyas Kamboh; Kenneth M Kaufman; Leah C Kottyan; Dalila Pinto; Stephen W Scherer; Marta E Alarcón-Riquelme; Elisa Docampo; Xavier Estivill; Ahmet Gül; Carl D Langefeld; Susan Thompson; Eleftheria Zeggini; Daniel L Kastner; Patricia Woo; Wendy Thomson
Journal:  Ann Rheum Dis       Date:  2016-12-07       Impact factor: 19.103

10.  High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction.

Authors:  Gang Li; Marta Martínez-Bonet; Di Wu; Yu Yang; Jing Cui; Hung N Nguyen; Pierre Cunin; Anaïs Levescot; Ming Bai; Harm-Jan Westra; Yukinori Okada; Michael B Brenner; Soumya Raychaudhuri; Eric A Hendrickson; Richard L Maas; Peter A Nigrovic
Journal:  Nat Genet       Date:  2018-07-16       Impact factor: 38.330
View more
  1 in total

1.  Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Authors:  Claudia Kedor; Joachim Listing; Jan Zernicke; Anja Weiß; Frank Behrens; Norbert Blank; Joerg Christoph Henes; Joern Kekow; Andrea Rubbert-Roth; Hendrik Schulze-Koops; Eva Seipelt; Christof Specker; Eugen Feist
Journal:  Ann Rheum Dis       Date:  2020-05-13       Impact factor: 27.973
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.